Bicycle Therapeutics plc
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5ā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.44
Price-1.08%
-$0.07
1Y
Price
Market Cap
$446.218m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-2651.8%
EBITDA Margin-2703.8%
Net Profit Margin-2509.7%
Free Cash Flow MarginRevenue
$19.281m
-45.3%
1y CAGR+24.0%
3y CAGR+23.9%
5y CAGREarnings
-$242.362m
-43.4%
1y CAGR-32.4%
3y CAGR-41.5%
5y CAGREPS
-$3.50
-20.7%
1y CAGR-3.8%
3y CAGR-13.4%
5y CAGRBook Value
$668.915m
$832.184m
Assets$163.269m
Liabilities$7.197m
DebtDebt to Assets
0.9%
-
Debt to EBITDAFree Cash Flow
-$210.623m
-26.9%
1y CAGR-49.5%
3y CAGR-168.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company